{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:38:39Z","timestamp":1684298319932},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,8,13]],"date-time":"2010-08-13T00:00:00Z","timestamp":1281657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00393-009-0530-7","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T18:09:19Z","timestamp":1281550159000},"page":"581-593","source":"Crossref","is-referenced-by-count":2,"title":["IL-1-Antagonisten"],"prefix":"10.1007","volume":"69","author":[{"given":"I.","family":"K\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,13]]},"reference":[{"key":"530_CR1","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1073\/pnas.81.24.7907","volume":"81","author":"Auron","year":"1984","unstructured":"Auron PE, Webb AC, Rosenwasser LJ et al (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 81:7907\u20137911","journal-title":"Proc Natl Acad Sci U S A"},{"key":"530_CR2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","volume":"6","author":"Gabay","year":"2010","unstructured":"Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232\u2013241","journal-title":"Nat Rev Rheumatol"},{"key":"530_CR3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"Dinarello","year":"2009","unstructured":"Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519\u2013550","journal-title":"Annu Rev Immunol"},{"key":"530_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4065\/84.2.105","volume":"84","author":"Dinarello","year":"2009","unstructured":"Dinarello CA (2009) Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering\/indolent myeloma to active disease. Mayo Clin Proc 84:105\u2013107","journal-title":"Mayo Clin Proc"},{"key":"530_CR5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni.1703","volume":"10","author":"Franchi","year":"2009","unstructured":"Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10:241\u2013247","journal-title":"Nat Immunol"},{"key":"530_CR6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2009.02.006","volume":"30","author":"Thomas","year":"2009","unstructured":"Thomas PG, Dash P, Aldridge JR Jr et al (2009) The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30:566\u2013575","journal-title":"Immunity"},{"key":"530_CR7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"Ghiringhelli","year":"2009","unstructured":"Ghiringhelli F, Apetoh L, Tesniere A et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170\u20131178","journal-title":"Nat Med"},{"key":"530_CR8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","volume":"223","author":"Arend","year":"2008","unstructured":"Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18 and IL-33 families of cytokines. Immunol Rev 223:20\u201338","journal-title":"Immunol Rev"},{"key":"530_CR9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0083-6729(06)74016-X","volume":"74","author":"Jacques","year":"2006","unstructured":"Jacques C, Gosset M, Berenbaum F, Gabay C (2006) The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 74:371\u2013403","journal-title":"Vitam Horm"},{"key":"530_CR10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","volume":"8","author":"Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942\u2013949","journal-title":"Nat Immunol"},{"key":"530_CR11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/BOR.0b013e3282fa13b4","volume":"20","author":"Finckh","year":"2008","unstructured":"Finckh A, Gabay C (2008) At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol 20:269\u2013275","journal-title":"Curr Opin Rheumatol"},{"key":"530_CR12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.1780390212","volume":"39","author":"Drevlow","year":"1996","unstructured":"Drevlow BE, Lovis R, Haag MA et al (1996) Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 39:257\u2013265","journal-title":"Arthritis Rheum"},{"key":"530_CR13","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"Bresnihan","year":"1998","unstructured":"Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196\u20132204","journal-title":"Arthritis Rheum"},{"key":"530_CR14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","volume":"46","author":"Cohen","year":"2002","unstructured":"Cohen S, Hurd E, Cush J et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614\u2013624","journal-title":"Arthritis Rheum"},{"key":"530_CR15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","volume":"43","author":"Jiang","year":"2000","unstructured":"Jiang Y, Genant HK, Watt I et al (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001\u20131009","journal-title":"Arthritis Rheum"},{"key":"530_CR16","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","volume":"50","author":"Genovese","year":"2004","unstructured":"Genovese MC, Cohen S, Moreland L et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412\u20131419","journal-title":"Arthritis Rheum"},{"key":"530_CR17","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","volume":"63","author":"Cohen","year":"2004","unstructured":"Cohen SB, Moreland LW, Cush JJ et al (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062\u20131068","journal-title":"Ann Rheum Dis"},{"key":"530_CR18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","volume":"48","author":"Fleischmann","year":"2003","unstructured":"Fleischmann RM, Schechtman J, Bennett R et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48:927\u2013934","journal-title":"Arthritis Rheum"},{"key":"530_CR19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","volume":"65","author":"Fleischmann","year":"2006","unstructured":"Fleischmann RM, Tesser J, Schiff MH et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65:1006\u20131012","journal-title":"Ann Rheum Dis"},{"key":"530_CR20","doi-asserted-by":"crossref","unstructured":"Nixon R, Bansback N, Brennan A (2007) The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 46:1140\u20131147","DOI":"10.1093\/rheumatology\/kem072"},{"key":"530_CR21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jbspin.2006.10.006","volume":"74","author":"Lequerre","year":"2007","unstructured":"Lequerre T, Vittecoq O, Loet X le (2007) What is the role for interleukin-1 receptor antagonist in rheumatic disease? Joint Bone Spine 74:223\u2013226","journal-title":"Joint Bone Spine"},{"key":"530_CR22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","volume":"36","author":"Mertens","year":"2009","unstructured":"Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36:1118\u20131125","journal-title":"J Rheumatol"},{"key":"530_CR23","doi-asserted-by":"crossref","unstructured":"Singh JA, Christensen R, Wells GA et al (2010) Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). The Cochrane Library","DOI":"10.1590\/S1516-31802010000500013"},{"key":"530_CR24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10555-010-9229-0","volume":"29","author":"Dinarello","year":"2010","unstructured":"Dinarello CA (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29:317\u2013329","journal-title":"Cancer Metastasis Rev"},{"key":"530_CR25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/art.20115","volume":"50","author":"Buch","year":"2004","unstructured":"Buch MH, Bingham SJ, Seto Y et al (2004) Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum 50:725\u2013728","journal-title":"Arthritis Rheum"},{"key":"530_CR26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/eji.201040319","volume":"40","author":"Dinarello","year":"2010","unstructured":"Dinarello CA (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40:599\u2013606","journal-title":"Eur J Immunol"},{"key":"530_CR27","first-page":"CD005121","volume":"Rev","author":"Mertens","year":"2009","unstructured":"Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev: CD005121","journal-title":"Cochrane Database Syst"},{"key":"530_CR28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s00393-009-0542-3","volume":"68","author":"Manger","year":"2009","unstructured":"Manger B, Gaubitz M, Michels H (2009) Recommendations on therapy using interleukin-1beta-blocking agents. Z Rheumatol 68:766\u2013771","journal-title":"Z Rheumatol"},{"key":"530_CR29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0029-1220906","volume":"34","author":"Wollenhaupt","year":"2009","unstructured":"Wollenhaupt JAR, Backhaus M, Baerwald C et al (2009) Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen 2009. Aktuelle Rheumatologie 34:234\u2013239","journal-title":"Aktuelle Rheumatologie"},{"key":"530_CR30","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964\u2013975","journal-title":"Ann Rheum Dis"},{"key":"530_CR31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00393-009-0449-z","volume":"68","author":"Kotter","year":"2009","unstructured":"Kotter I, Schedel J, Kummerle-Deschner JB (2009) Periodic fever syndrome\/autoinflammatory syndrome. Z Rheumatol 68:137\u2013148","journal-title":"Z Rheumatol"},{"key":"530_CR32","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar2438","volume":"10","author":"Alten","year":"2008","unstructured":"Alten R, Gram H, Joosten LA et al (2008) The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10:R67","journal-title":"Arthritis Res Ther"},{"key":"530_CR33","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T et al (2004) The German Etanercept Registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638\u20131644","journal-title":"Ann Rheum Dis"},{"key":"530_CR34","first-page":"S632","volume":"58","author":"Quartier","year":"2008","unstructured":"Quartier P, Allantaz, F, Cimaz, R et al (2008) A multicentric, double-blind trial of anakinra versus placebo in systemic-onset juvenile idiopathic arthritis (ANAJIS trial): efficacy and tolerance over 12 months. Arthritis Rheum 58:S632","journal-title":"Arthritis Rheum"},{"key":"530_CR35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"Ilowite","year":"2009","unstructured":"Ilowite N, Porras O, Reiff A et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28:129\u2013137","journal-title":"Clin Rheumatol"},{"key":"530_CR36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"Lequerre","year":"2008","unstructured":"Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67:302\u2013308","journal-title":"Ann Rheum Dis"},{"key":"530_CR37","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasiglie D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505\u20131515","journal-title":"Arthritis Rheum"},{"key":"530_CR38","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1002\/art.21556","volume":"54","author":"Lovell","year":"2006","unstructured":"Lovell DJ, Gianinni EH, Kimura Y et al (2006) Preliminary evidence for bioactivity of IL-1 trap (Rilonacept), a long acting Il-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 54:S325","journal-title":"Arthritis Rheum"},{"key":"530_CR39","first-page":"S768","volume":"60","author":"Lovell","year":"2009","unstructured":"Lovell DJ, Giannini EH, Kimura Y et al (2009) Long-term safety and efficacy of Rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum 60:S768","journal-title":"Arthritis Rheum"},{"key":"530_CR40","doi-asserted-by":"crossref","first-page":"S2055","DOI":"10.1002\/art.24616","volume":"60","author":"Ruperto","year":"2009","unstructured":"Ruperto N, Quartier P, Wulfraat N et al (2009) for PRINTO. Evaluation of safety and preliminary efficacy of canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, in children with systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 60:S2055","journal-title":"Arthritis Rheum"},{"key":"530_CR41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","volume":"355","author":"Goldbach-Mansky","year":"2006","unstructured":"Goldbach-Mansky R, Dailey NJ, Canna SW et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581\u2013592","journal-title":"N Engl J Med"},{"key":"530_CR42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.23261","volume":"58","author":"Yamazaki","year":"2008","unstructured":"Yamazaki T, Masumoto J, Agematsu K et al (2008) Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 58:864\u2013868","journal-title":"Arthritis Rheum"},{"key":"530_CR43","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"Hoffman","year":"2008","unstructured":"Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443\u20132452","journal-title":"Arthritis Rheum"},{"key":"530_CR44","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416\u20132425","journal-title":"N Engl J Med"},{"key":"530_CR45","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","volume":"360","author":"Reddy","year":"2009","unstructured":"Reddy S, Jia S, Geoffrey R et al (2009) An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 360:2438\u20132444","journal-title":"N Engl J Med"},{"key":"530_CR46","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426\u20132437","journal-title":"N Engl J Med"},{"key":"530_CR47","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"Gattorno","year":"2008","unstructured":"Gattorno M, Pelagatti MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516\u20131520","journal-title":"Arthritis Rheum"},{"key":"530_CR48","first-page":"S535","volume":"58","author":"Bensen","year":"2008","unstructured":"Bensen W, Cardiel MH, Forejtova S et al (2008) Results of a phase 2 randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R type I) in patients with rheumatoid arthritis (abstract No 994). Arthritis Rheum 58 (Suppl):S535 (abstract No 994). Arthritis Rheum 58 (Suppl):S535","journal-title":"Arthritis Rheum"},{"key":"530_CR49","first-page":"3415","volume":"46","author":"Pavelka","year":"2002","unstructured":"Pavelka K (2002) Clinical effects of prainacasan (PRAL), an orally-active interleukin-1\u03b2 converting enzyme (ICE) inhibitor, in a 285 patient phase II trial in rheumatoid arthritis (abstract LB02). Arthritis Rheum 46:3415","journal-title":"Arthritis Rheum"},{"key":"530_CR50","doi-asserted-by":"crossref","unstructured":"Alpay N, Sumnu A, Caliskan Y et al (2010) Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int [Epub ahead of print]","DOI":"10.1007\/s00296-010-1474-6"},{"key":"530_CR51","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-146-11-200706050-00023","volume":"146","author":"Belkhir","year":"2007","unstructured":"Belkhir R, Moulonguet-Doleris L, Hachulla E et al (2007) Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 146:825\u2013826","journal-title":"Ann Intern Med"},{"key":"530_CR52","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00431-007-0547-3","volume":"167","author":"Calligaris","year":"2008","unstructured":"Calligaris L, Marchetti F, Tommasini A, Ventura A (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167:695\u2013696","journal-title":"Eur J Pediatr"},{"key":"530_CR53","first-page":"237","volume":"Clin","author":"Fernandez","year":"2009","unstructured":"Fernandez Garcia MI, Albornoz Lopez R, Cuevas Asencio I (2009) Anakinra in familial Mediterranean fever. Med Clin (Barc) 132:237\u2013238","journal-title":"Med"},{"key":"530_CR54","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2362.2007.01868.x","volume":"37","author":"Gattringer","year":"2007","unstructured":"Gattringer R, Lagler H, Gattringer KB et al (2007) Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 37:912\u2013914","journal-title":"Eur J Clin Invest"},{"key":"530_CR55","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/ard.2007.071498","volume":"66","author":"Kuijk","year":"2007","unstructured":"Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66:1545\u20131546","journal-title":"Ann Rheum Dis"},{"key":"530_CR56","first-page":"489","volume":"66","author":"Mitroulis","year":"2008","unstructured":"Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K (2008) Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 66:489\u2013491","journal-title":"Neth J Med"},{"key":"530_CR57","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/ndt\/gfn646","volume":"24","author":"Moser","year":"2009","unstructured":"Moser C, Pohl G, Haslinger I et al (2009) Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24:676\u2013678","journal-title":"Nephrol Dial Transplant"},{"key":"530_CR58","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jbspin.2008.04.001","volume":"75","author":"Roldan","year":"2008","unstructured":"Roldan R, Ruiz AM, Miranda MD, Collantes E (2008) Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 75:504\u2013505","journal-title":"Joint Bone Spine"},{"key":"530_CR59","first-page":"416","volume":"19","author":"Rozenbaum","year":"1992","unstructured":"Rozenbaum M, Katz R, Rozner I, Pollack S (1992) Decreased interleukin 1 activity released from circulating monocytes of patients with familial Mediterranean fever during in vitro stimulation by lipopolysaccharide. J Rheumatol 19:416\u2013418","journal-title":"J Rheumatol"},{"key":"530_CR60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard.2005.038091","volume":"65","author":"Rynne","year":"2006","unstructured":"Rynne M, Maclean C, Bybee A et al (2006) Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 65:533\u2013534","journal-title":"Ann Rheum Dis"},{"key":"530_CR61","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/ard.2004.032060","volume":"64","author":"Alexander","year":"2005","unstructured":"Alexander T, Klotz O, Feist E et al (2005) Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist. Ann Rheum Dis 64:1245\u20131246","journal-title":"Ann Rheum Dis"},{"key":"530_CR62","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","volume":"348","author":"Hawkins","year":"2003","unstructured":"Hawkins PN, Lachmann HJ, McDermott MF (2003) Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348:2583\u20132584","journal-title":"N Engl J Med"},{"key":"530_CR63","first-page":"302","volume":"67","author":"Bodar","year":"2009","unstructured":"Bodar EJ, Simon A, Visser M de, Meer JW van der (2009) Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med 67:302\u2013305","journal-title":"Neth J Med"},{"key":"530_CR64","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/03009740600938647","volume":"36","author":"Botsios","year":"2007","unstructured":"Botsios C, Sfriso P, Punzi L, Todesco S (2007) Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra. Scand J Rheumatol 36:236\u2013237","journal-title":"Scand J Rheumatol"},{"key":"530_CR65","doi-asserted-by":"crossref","unstructured":"Chu CQ (o J) Chronic urticaria and arthritis with polyclonal IgA: rapid response and clinical remission with interleukin 1 blockade. J Rheumatol 37:881\u2013882","DOI":"10.3899\/jrheum.091200"},{"key":"530_CR66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10067-007-0734-7","volume":"27","author":"Kashiwagi","year":"2008","unstructured":"Kashiwagi Y, Kawashima H, Nishimata S et al (2008) Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome. Clin Rheumatol 27:277\u2013279","journal-title":"Clin Rheumatol"},{"key":"530_CR67","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1136\/ard.2005.036749","volume":"64","author":"Seitz","year":"2005","unstructured":"Seitz M, Kamgang RK, Simon HU, Villiger PM (2005) Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. Ann Rheum Dis 64:1802\u20131803","journal-title":"Ann Rheum Dis"},{"key":"530_CR68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2177\/jsci.30.108","volume":"30","author":"Sugiura","year":"2007","unstructured":"Sugiura H, Matsubayashi T (2007) Clinical features of CINCA syndrome: effects and problems of IL-1Ra. Nihon Rinsho Meneki Gakkai Kaishi 30:108\u2013113","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"530_CR69","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ajmg.a.31148","volume":"140","author":"Boschan","year":"2006","unstructured":"Boschan C, Witt O, Lohse P et al (2006) Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. Am J Med Genet A 140:883\u2013886","journal-title":"Am J Med Genet A"},{"key":"530_CR70","doi-asserted-by":"crossref","unstructured":"Lequerre T, Vittecoq O, Pouplin S et al (2007) Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra. Rheumatology (Oxford) 46:1860\u20131862","DOI":"10.1093\/rheumatology\/kem258"},{"key":"530_CR71","first-page":"260","volume":"63","author":"Bodar","year":"2005","unstructured":"Bodar EJ, Hilst JC van der, Drenth JP et al (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63:260\u2013264","journal-title":"Neth J Med"},{"key":"530_CR72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.amjmed.2004.02.039","volume":"117","author":"Simon","year":"2004","unstructured":"Simon A, Bodar EJ, Hilst JC van der et al (2004) Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 117:208\u2013210","journal-title":"Am J Med"},{"key":"530_CR73","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","volume":"161","author":"Brenner","year":"2009","unstructured":"Brenner M, Ruzicka T, Plewig G et al (2009) Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 161:1199\u20131201","journal-title":"Br J Dermatol"},{"key":"530_CR74","doi-asserted-by":"crossref","unstructured":"Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ (2005) Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44:406\u2013408","DOI":"10.1093\/rheumatology\/keh479"},{"key":"530_CR75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/s10165-009-0254-1","volume":"20","author":"Tamaki","year":"2010","unstructured":"Tamaki H, Shimizu H, Hiraoka E et al (2010) Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still\u2019s disease. Mod Rheumatol 20:200\u2013204","journal-title":"Mod Rheumatol"},{"key":"530_CR76","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","volume":"69","author":"Naumann","year":"2010","unstructured":"Naumann L, Feist E, Natusch A et al (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still\u2019s disease. Ann Rheum Dis 69:466\u2013467","journal-title":"Ann Rheum Dis"},{"key":"530_CR77","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1468-3083.2008.2746.x","volume":"23","author":"Gesierich","year":"2009","unstructured":"Gesierich A, Stoevesandt J, Kneitz C et al (2009) Adult-onset Still\u2019s disease: an uncommon differential diagnosis of urticaria and treatment with anakinra. J Eur Acad Dermatol Venereol 23:104\u2013106","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"530_CR78","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3899\/jrheum.080150","volume":"35","author":"Youssef","year":"2008","unstructured":"Youssef J, Lazaro E, Blanco P, Viallard JF (2008) Blockade of interleukin 1 receptor in Still\u2019s disease affects activation of peripheral T-lymphocytes. J Rheumatol 35:2453\u20132456","journal-title":"J Rheumatol"},{"key":"530_CR79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ard.2007.082859","volume":"67","author":"Woo","year":"2008","unstructured":"Woo P (2008) Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann Rheum Dis 67:281\u2013282","journal-title":"Ann Rheum Dis"},{"key":"530_CR80","first-page":"933","volume":"26","author":"Priori","year":"2008","unstructured":"Priori R, Ceccarelli F, Barone F et al (2008) Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still\u2019s disease. Clin Exp Rheumatol 26:933\u2013937","journal-title":"Clin Exp Rheumatol"},{"key":"530_CR81","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10067-007-0791-y","volume":"27","author":"Mylona","year":"2008","unstructured":"Mylona E, Golfinopoulou S, Samarkos M et al (2008) Acute hepatitis in adult Still\u2019s disease during corticosteroid treatment successfully treated with anakinra. Clin Rheumatol 27:659\u2013661","journal-title":"Clin Rheumatol"},{"key":"530_CR82","first-page":"939","volume":"35","author":"Maier","year":"2008","unstructured":"Maier J, Birkenfeld G, Pfirstinger J et al (2008) Effective treatment of steroid refractory adult-onset Still\u2019s disease with anakinra. J Rheumatol 35:939\u2013941","journal-title":"J Rheumatol"},{"key":"530_CR83","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/13543784.17.3.349","volume":"17","author":"Kalliolias","year":"2008","unstructured":"Kalliolias GD, Liossis SN (2008) The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17:349\u2013359","journal-title":"Expert Opin Investig Drugs"},{"key":"530_CR84","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/03009740701340081","volume":"36","author":"Youm","year":"2007","unstructured":"Youm JY, Woo JH, Kim TH et al (2007) Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in Korean patients with adult-onset Still\u2019s disease. Scand J Rheumatol 36:390\u2013393","journal-title":"Scand J Rheumatol"},{"key":"530_CR85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/ard.2006.060541","volume":"66","author":"Ruiz","year":"2007","unstructured":"Ruiz PJ, Masliah E, Doherty TA et al (2007) Cardiac death in a patient with adult-onset Still\u2019s disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 66:422\u2013423","journal-title":"Ann Rheum Dis"},{"key":"530_CR86","first-page":"892","volume":"34","author":"Quartuccio","year":"2007","unstructured":"Quartuccio L, De Vita S (2007) Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still\u2019s disease. J Rheumatol 34:892\u2013893","journal-title":"J Rheumatol"},{"key":"530_CR87","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","volume":"37","author":"Kotter","year":"2007","unstructured":"Kotter I, Wacker A, Koch S et al (2007) Anakinra in patients with treatment-resistant adult-onset Still\u2019s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37:189\u2013197","journal-title":"Semin Arthritis Rheum"},{"key":"530_CR88","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.2006.066381","volume":"66","author":"Kalliolias","year":"2007","unstructured":"Kalliolias GD, Georgiou PE, Antonopoulos IA et al (2007) Anakinra treatment in patients with adult-onset Still\u2019s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66:842\u2013843","journal-title":"Ann Rheum Dis"},{"key":"530_CR89","first-page":"758","volume":"25","author":"Guignard","year":"2007","unstructured":"Guignard S, Dien G, Dougados M (2007) Severe systemic inflammatory response syndrome in a patient with adult onset Still\u2019s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 25:758\u2013759","journal-title":"Clin Exp Rheumatol"},{"key":"530_CR90","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","volume":"64","author":"Vasques","year":"2005","unstructured":"Vasques GFM, Parreira SMJ, Canas da Silva J (2005) Refractory adult onset Still\u2019s disease successfully treated with anakinra. Ann Rheum Dis 64:647\u2013648","journal-title":"Ann Rheum Dis"},{"key":"530_CR91","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","volume":"52","author":"Fitzgerald","year":"2005","unstructured":"Fitzgerald AA, Leclercq SA, Yan A et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease. Arthritis Rheum 52:1794\u20131803","journal-title":"Arthritis Rheum"},{"key":"530_CR92","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.rhu.0000089966.48691.7f","volume":"9","author":"Rudinskaya","year":"2003","unstructured":"Rudinskaya A, Trock DH (2003) Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol 9:330\u2013332","journal-title":"J Clin Rheumatol"},{"key":"530_CR93","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A et al (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149:284\u2013286","journal-title":"Ann Intern Med"},{"key":"530_CR94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-3083.2008.02708.x","volume":"23","author":"Wastiaux","year":"2009","unstructured":"Wastiaux H, Barbarot S, Gagey-Caron V et al (2009) Schnitzler syndrome: a dramatic improvement with anakinra. J Eur Acad Dermatol Venereol 23:85\u201387","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"530_CR95","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3324\/haematol.2009.005975","volume":"94","author":"Deuren","year":"2009","unstructured":"Deuren M van, Kroot JJ, Swinkels DW (2009) Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler\u2019s syndrome treated with IL-1 receptor antagonist. Haematologica 94:1297\u20131300","journal-title":"Haematologica"},{"key":"530_CR96","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1365-4632.2009.04151.x","volume":"48","author":"Schuster","year":"2009","unstructured":"Schuster C, Kranke B, Aberer E et al (2009) Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Int J Dermatol 48:1190\u20131194","journal-title":"Int J Dermatol"},{"key":"530_CR97","first-page":"1196","volume":"55","author":"Adam","year":"2009","unstructured":"Adam Z, Krejci M, Pour L, Hajek R (2009) Evaluation of 2-year treatment of Schnitzler syndrome (urticarial exanthema, monoclonal IgM gammopathy and osteolytic-osteosclerotic skeletal changes) using Anakinra (Kineret). Vnitr Lek 55:1196\u20131197","journal-title":"Vnitr Lek"},{"key":"530_CR98","first-page":"358","volume":"Clin","author":"Saiz","year":"2008","unstructured":"Saiz E, Galvez J, Mora A, Contreras L (2008) Anakinra and Schnitzler\u2019s syndrome. Med Clin (Barc) 130:358\u2013359","journal-title":"Med"},{"key":"530_CR99","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2007.09.021","volume":"121","author":"Ryan","year":"2008","unstructured":"Ryan JG, Koning HD de, Beck LA et al (2008) IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 121:260\u2013262","journal-title":"J Allergy Clin Immunol"},{"key":"530_CR100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2340\/00015555-0352","volume":"88","author":"Kluger","year":"2008","unstructured":"Kluger N, Riviere S, Guillot B, Bessis D (2008) Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler\u2019s syndrome. Acta Derm Venereol 88:287\u2013288","journal-title":"Acta Derm Venereol"},{"key":"530_CR101","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1081-1206(10)60064-6","volume":"100","author":"Frischmeyer-Guerrerio","year":"2008","unstructured":"Frischmeyer-Guerrerio PA, Rachamalla R, Saini SS (2008) Remission of Schnitzler syndrome after treatment with anakinra. Ann Allergy Asthma Immunol 100:617\u2013619","journal-title":"Ann Allergy Asthma Immunol"},{"key":"530_CR102","first-page":"354","volume":"26","author":"Dybowski","year":"2008","unstructured":"Dybowski F, Sepp N, Bergerhausen HJ, Braun J (2008) Successful use of anakinra to treat refractory Schnitzler\u2019s syndrome. Clin Exp Rheumatol 26:354\u2013357","journal-title":"Clin Exp Rheumatol"},{"key":"530_CR103","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/1757-1626-1-348","volume":"1","author":"Devlin","year":"2008","unstructured":"Devlin LA, Wright G, Edgar JD (2008) A rare cause of a common symptom, anakinra is effective in the urticaria of Schnitzler Syndrome: a case report. Cases J 1:348","journal-title":"Cases J"},{"key":"530_CR104","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jaad.2006.05.057","volume":"56","author":"Schneider","year":"2007","unstructured":"Schneider SW, Gaubitz M, Luger TA, Bonsmann G (2007) Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 56:S120\u2013S122","journal-title":"J Am Acad Dermatol"},{"key":"530_CR105","first-page":"931","volume":"25","author":"Gilson","year":"2007","unstructured":"Gilson M, Abad S, Larroche C, Dhote R (2007) Treatment of Schnitzler\u2019s syndrome with anakinra. Clin Exp Rheumatol 25:931","journal-title":"Clin Exp Rheumatol"},{"key":"530_CR106","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2007.03.036","volume":"57","author":"Eiling","year":"2007","unstructured":"Eiling E, Moller M, Kreiselmaier I et al (2007) Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 57:361\u2013364","journal-title":"J Am Acad Dermatol"},{"key":"530_CR107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1440-0960.2007.00375.x","volume":"48","author":"Crouch","year":"2007","unstructured":"Crouch R, Akhras V, Sarkany R (2007) Schnitzler\u2019s syndrome: successful treatment with anakinra. Australas J Dermatol 48:178\u2013181","journal-title":"Australas J Dermatol"},{"key":"530_CR108","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/ard.2005.045245","volume":"65","author":"Koning","year":"2006","unstructured":"Koning HD de, Bodar EJ, Simon A et al (2006) Beneficial response to anakinra and thalidomide in Schnitzler\u2019s syndrome. Ann Rheum Dis 65:542\u2013544","journal-title":"Ann Rheum Dis"},{"key":"530_CR109","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.21101","volume":"52","author":"Martinez-Taboada","year":"2005","unstructured":"Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL (2005) Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 52:2226\u20132227","journal-title":"Arthritis Rheum"},{"key":"530_CR110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0091-6749(91)90335-L","volume":"88","author":"Saurat","year":"1991","unstructured":"Saurat JH, Schifferli J, Steiger G et al (1991) Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution and receptor-binding inhibition \u2013 higher frequency in Schnitzler\u2019s syndrome (urticaria and macroglobulinemia). J Allergy Clin Immunol 88:244\u2013256","journal-title":"J Allergy Clin Immunol"},{"key":"530_CR111","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3899\/jrheum.091046","volume":"37","author":"Durand","year":"2010","unstructured":"Durand M, Troyanov Y, Laflamme P, Gregoire G (2010) Macrophage activation syndrome treated with anakinra. J Rheumatol 37:879\u2013880","journal-title":"J Rheumatol"},{"key":"530_CR112","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"Kelly","year":"2008","unstructured":"Kelly A, Ramanan AV (2008) A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 4:615\u2013620","journal-title":"Nat Clin Pract Rheumatol"},{"key":"530_CR113","first-page":"2081","volume":"33","author":"Behrens","year":"2006","unstructured":"Behrens EM, Kreiger PA, Cherian S, Cron RQ (2006) Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 33:2081\u20132084","journal-title":"J Rheumatol"},{"key":"530_CR114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/(SICI)1096-911X(199607)27:1<21::AID-MPO5>3.0.CO;2-W","volume":"27","author":"Henter","year":"1996","unstructured":"Henter JI, Andersson B, Elinder G et al (1996) Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 27:21\u201325","journal-title":"Med Pediatr Oncol"},{"key":"530_CR115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000204864","volume":"85","author":"Ishii","year":"1991","unstructured":"Ishii E, Ohga S, Aoki T et al (1991) Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor. Acta Haematol 85:93\u201399","journal-title":"Acta Haematol"},{"key":"530_CR116","doi-asserted-by":"crossref","unstructured":"Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C (2006) Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 45:491\u2013492","DOI":"10.1093\/rheumatology\/kel041"},{"key":"530_CR117","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jbspin.2008.02.011","volume":"75","author":"Wendling","year":"2008","unstructured":"Wendling D, Govindaraju S, Prati C et al (2008) Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 75:622\u2013624","journal-title":"Joint Bone Spine"},{"key":"530_CR118","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2133.1996.tb06975.x","volume":"134","author":"Bourke","year":"1996","unstructured":"Bourke JF, Jones JL, Fletcher A, Graham-Brown RA (1996) An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1 in 12 cases of Sweet\u2019s syndrome. Br J Dermatol 134:705\u2013709","journal-title":"Br J Dermatol"},{"key":"530_CR119","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/ard.2006.068254","volume":"67","author":"Delluc","year":"2008","unstructured":"Delluc A, Limal N, Puechal X et al (2008) Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 67:278\u2013279","journal-title":"Ann Rheum Dis"},{"key":"530_CR120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.24174","volume":"60","author":"Picco","year":"2009","unstructured":"Picco P, Brisca G, Traverso F et al (2009) Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 60:264\u2013268","journal-title":"Arthritis Rheum"},{"key":"530_CR121","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR et al (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68:1613\u20131617","journal-title":"Ann Rheum Dis"},{"key":"530_CR122","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/RHU.0b013e3181be2423","volume":"15","author":"Singh","year":"2009","unstructured":"Singh D, Huston KK (2009) IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol 15:366","journal-title":"J Clin Rheumatol"},{"key":"530_CR123","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/art.24694","volume":"61","author":"Gratton","year":"2009","unstructured":"Gratton SB, Scalapino KJ, Fye KH (2009) Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 61:1268\u20131270","journal-title":"Arthritis Rheum"},{"key":"530_CR124","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:R28","journal-title":"Arthritis Res Ther"},{"key":"530_CR125","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","volume":"56","author":"Pope","year":"2007","unstructured":"Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56:3183\u20133188","journal-title":"Arthritis Rheum"},{"key":"530_CR126","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","volume":"66","author":"McGonagle","year":"2007","unstructured":"McGonagle D, Tan AL, Shankaranarayana S et al (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66:1683\u20131684","journal-title":"Ann Rheum Dis"},{"key":"530_CR127","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.23119","volume":"58","author":"McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J et al (2008) Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58:631\u2013633","journal-title":"Arthritis Rheum"},{"key":"530_CR128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nrrheum.2009.121","volume":"5","author":"Martel-Pelletier","year":"2009","unstructured":"Martel-Pelletier J, Pelletier JP (2009) Osteoarthritis: A single injection of anakinra for treating knee OA? Nat Rev Rheumatol 5:363\u2013364","journal-title":"Nat Rev Rheumatol"},{"key":"530_CR129","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.2008.094284","volume":"68","author":"Bacconnier","year":"2009","unstructured":"Bacconnier L, Jorgensen C, Fabre S (2009) Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis 68:1078\u20131079","journal-title":"Ann Rheum Dis"},{"key":"530_CR130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.joca.2007.07.008","volume":"16","author":"Yang","year":"2008","unstructured":"Yang KG, Raijmakers NJ, Arkel ER van et al (2008) Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 16:498\u2013505","journal-title":"Osteoarthritis Cartilage"},{"key":"530_CR131","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-007-0019-9","volume":"9","author":"Iqbal","year":"2007","unstructured":"Iqbal I, Fleischmann R (2007) Treatment of osteoarthritis with anakinra. Curr Rheumatol Rep 9:31\u201335","journal-title":"Curr Rheumatol Rep"},{"key":"530_CR132","first-page":"1317","volume":"32","author":"Chevalier","year":"2005","unstructured":"Chevalier X, Giraudeau B, Conrozier T et al (2005) Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 32:1317\u20131323","journal-title":"J Rheumatol"},{"key":"530_CR133","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00113-004-0885-9","volume":"107","author":"Stengel","year":"2004","unstructured":"Stengel D, Ekkernkamp A, Wich M (2004) Intra-articular therapy with autologous interleukin-1 receptor antagonist in osteoarthritis. Innovation or quackery? Unfallchirurg 107:1103\u20131106","journal-title":"Unfallchirurg"},{"key":"530_CR134","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.gt.3301608","volume":"9","author":"Frisbie","year":"2002","unstructured":"Frisbie DD, Ghivizzani SC, Robbins PD et al (2002) Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 9:12\u201320","journal-title":"Gene Ther"},{"key":"530_CR135","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0002-9440(10)65368-0","volume":"154","author":"Fernandes","year":"1999","unstructured":"Fernandes J, Tardif G, Martel-Pelletier J et al (1999) In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 154:1159\u20131169","journal-title":"Am J Pathol"},{"key":"530_CR136","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1517\/14712590903136688","volume":"9","author":"Maedler","year":"2009","unstructured":"Maedler K, Dharmadhikari G, Schumann DM, Storling J (2009) Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9:1177\u20131188","journal-title":"Expert Opin Biol Ther"},{"key":"530_CR137","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","volume":"32","author":"Larsen","year":"2009","unstructured":"Larsen CM, Faulenbach M, Vaag A et al (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663\u20131668","journal-title":"Diabetes Care"},{"key":"530_CR138","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ncpendmet0783","volume":"4","author":"Donath","year":"2008","unstructured":"Donath MY, Mandrup-Poulsen T (2008) The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat Clin Pract Endocrinol Metab 4:240\u2013241","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"530_CR139","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJMc071324","volume":"357","author":"Malozowski","year":"2007","unstructured":"Malozowski S, Sahlroot JT (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 357:302\u2013303","journal-title":"N Engl J Med"},{"key":"530_CR140","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"Larsen","year":"2007","unstructured":"Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517\u20131526","journal-title":"N Engl J Med"},{"key":"530_CR141","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/hrt.2009.168971","volume":"95","author":"Ikonomidis","year":"2009","unstructured":"Ikonomidis I, Tzortzis S, Lekakis J et al (2009) Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart 95:1502\u20131507","journal-title":"Heart"},{"key":"530_CR142","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","volume":"117","author":"Abbate","year":"2008","unstructured":"Abbate A, Salloum FN, Vecile E et al (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117:2670\u20132683","journal-title":"Circulation"},{"key":"530_CR143","doi-asserted-by":"crossref","unstructured":"Bennett AN, Tan AL, Coates LC et al (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 47:223\u2013224","DOI":"10.1093\/rheumatology\/kem302"},{"key":"530_CR144","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64:296\u2013298","journal-title":"Ann Rheum Dis"},{"key":"530_CR145","doi-asserted-by":"crossref","unstructured":"Colina M, Pizzirani C, Khodeir M et al (2010) Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford) 49:1416\u20131418","DOI":"10.1093\/rheumatology\/keq074"},{"key":"530_CR146","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2007.07.010","volume":"75","author":"Furlan","year":"2008","unstructured":"Furlan A, Botsios C, Ruffatti A et al (2008) Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report. Joint Bone Spine 75:366\u2013367","journal-title":"Joint Bone Spine"},{"key":"530_CR147","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2004.025858","volume":"64","author":"Ostendorf","year":"2005","unstructured":"Ostendorf B, Iking-Konert C, Kurz K et al (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64:630\u2013633","journal-title":"Ann Rheum Dis"},{"key":"530_CR148","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1191\/0961203304lu1047cr","volume":"13","author":"Moosig","year":"2004","unstructured":"Moosig F, Zeuner R, Renk C, Schroder JO (2004) IL-1RA in refractory systemic lupus erythematosus. Lupus 13:605\u2013606","journal-title":"Lupus"},{"key":"530_CR149","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","volume":"84","author":"Lust","year":"2009","unstructured":"Lust JA, Lacy MQ, Zeldenrust SR et al (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84:114\u2013122","journal-title":"Mayo Clin Proc"},{"key":"530_CR150","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/1535-7163.MCT-10-0156","volume":"9","author":"El-Osta","year":"2010","unstructured":"El-Osta H, Janku F, Kurzrock R (2010) Successful treatment of Castleman\u2019s disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 9:1485\u20131488","journal-title":"Mol Cancer Ther"},{"key":"530_CR151","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MPH.0b013e31818ab31f","volume":"30","author":"Galeotti","year":"2008","unstructured":"Galeotti C, Tran TA, Franchi-Abella S et al (2008) IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. J Pediatr Hematol Oncol 30:920\u2013924","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0530-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0530-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0530-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T16:40:14Z","timestamp":1559407214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0530-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,13]]},"references-count":151,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0530-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,13]]}}}